Baxter Announces Acquisition of Apatech

Earlier today, it was reported through one of TSB's sources that Baxter announced the acquisition of Apatech. The tentative numbers are that the acquisition cost Baxter an estimated $240 million dollars up front with an additional $90 million if certain milestones are met. I guess this confirms an e-mail that TSB received over the weekend from one of our readers who thought that this deal was imminent.

If the deal rings true, it looks like Baxter is positioning itself in the industry as a potential foe of Orthovita. This will compliment their hemostasis line and potentially allow them to start evaluating other options. TSB wants to know what our readers have heard? Looks like any company that has a nice synthetic stands to cash out as the economy continues to rebound at a slow pace.